Level B· Emerging clinical evidence with positive signalsClinical TrialPubMed

Dynamic fabrication of tissue-engineered bone substitutes based on derived cancellous bone scaffold in a spinner flask bioreactor system.

Kedong S., Wenfang L., Yanxia Z., Hong W., Ze Y., Mayasari L.

Clinical Trial on Face & Skin, published in Appl Biochem Biotechnol (2014) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Appl Biochem Biotechnol (2014)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
25106897
DOI
10.1007/s12010-014-1132-7
Citations
19

Abstract (original English)

The in vitro dynamic fabrications of tissue-engineered bones were performed to assess the advantages of human adipose-derived stem cells (hADSCs) combined with acellular cancellous bone scaffold coming from fresh pig femur in a spinner flask compared with traditional static culture. In this study, the bio-derived cancellous bone was regarded as a biomimetic scaffold, and its surface appearance was observed under scanning electron microscopy (SEM). Moreover, its modulus of elasticity and chemical composition were measured with universal testing machine (UTM) and infrared detector, respectively. hADSCs were inoculated into cancellous bone scaffold at a density of 1 × 10(6) cells/mL and cultured in spinner flask and T-flask with osteogenic medium (OM) for 2 weeks, respectively. Following to this, the osteogenic differentiation was qualitatively and quantitatively detected with alkaline phosphatase (ALP) kits, and the cell growth and viability were assayed using Live/Dead staining; cell adhesion and extracellular matrix secretion were observed under a SEM. The average pore size of cancellous bone scaffold was 284.5 ± 83.62 μm, the elasticity modulus was 41.27 ± 15.63 MPa, and it also showed excellent biocompatibility. The hADSCs with multidifferentiation potentials were well proliferated, could grow to 90 % fusion within 5 days, and were therefore suitable to use as seed cells in t

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
Adipose TissueAdultAnimalsBioreactorsBone SubstitutesCell ProliferationCell SurvivalCells, CulturedFemaleFemur

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research